GFP IMAGING FOR IN VIVO HIGH-THROUGHPUT DRUG SCREENING
GFP IMAGING FOR IN VIVO HIGH-THROUGHPUT DRUG SCREENING
批准号:
6446853
负责人:
MENG YANG
金额:
$12.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-03-08 至 2003-02-28
中文摘要
该应用程序的目标是开发一种与临床相关的
体内高通量抗癌药物筛选。为了实现这一目标,我们将
进一步建立小鼠转移性肿瘤模型
荧光肿瘤可以在非侵入性,快速和外部成像
适用于高通量抗肿瘤筛选的实时方式,
抗转移和抗血管生成药物。作为迈向
为此,我们将绿色荧光蛋白(GFP)基因转化为绿色荧光蛋白,并进行了克隆
从生物发光水母Aequorea Victoria,变成了一系列50个人类
以及移植后体内稳定表达GFP的啮齿动物癌细胞株
合适的啮齿动物模型。我们已经证明了绿色荧光蛋白肿瘤在
大脑、肝脏和骨骼可以通过皮肤进行外部全身成像
通过荧光定量。在新的发展中,我们已经表明
肺内表达GFP的肿瘤和转移可以在外部成像。
高通量模型的开发将有以下具体目标:
1)确定可能是外部的转移性癌症所涉及的器官
实时检测肿瘤GFP表达。外部成像将是
与荧光肿瘤的直接成像比较;2)测定和
改进了外部成像的最大深度和最小肿瘤大小。
分辨率的提高将集中在信号/背景的增加上
比例,概述如下:1)表达GFP的超亮癌细胞克隆
将在体外选择增强大小和深度的图像分辨率后
体内移植;2)选择性滤光片、可调谐激光和双光子
将使用成像来最大化深度和大小分辨率;3)实时
肿瘤与转移生长、血管生成及抑制代表
将对药物进行成像和量化,以证明使用
一种快速抗肿瘤、抗转移和抗血管生成药物的模型
屏幕上。由光学成像和标准获得的剂量响应曲线
肿瘤测量将比较结肠、胰腺、前列腺癌、黑色素瘤和
肺肿瘤模型。
建议的商业应用:
所有主要癌症的外部可成像、基因荧光转移的小鼠模型
将开发快速筛选新的有效抗肿瘤、抗转移药物的类型
和抗血管生成药物。目前抗癌新药体内试验的市场规模
随着基因组学、蛋白质组学和组合技术等新技术的迅速发展
化学合成和高通量体外筛选提供了大量新的
必须在体内进行测试和验证的线索。
英文摘要
The goal of this application is the development of a clinically-relevant in
vivo high-throughput cancer drug screen. To achieve this goal, we will
further develop mouse models of metastatic cancer with genetically
fluorescent tumors that can be imaged externally in a non-invasive, rapid and
real-time manner suitable for high-throughput screening of anti-tumor,
anti-metastatic and anti-angiogenesis agents. As an important step toward
this goal, we have transduced the green fluorescent protein (GFP) gene, cloned
from the bioluminescent jellyfish Aequorea victoria, into a series of 50 human
and rodent cancer cell lines that stably express GFP in vivo after transplantation
to appropriate rodent models. We have already demonstrated that GFP tumors on
the brain, liver, and bone can be externally, transcutaneously whole-body imaged
quantitatively by fluorescence. In new developments, we have shown that
GFP-expressing tumors and metastasis in the lung can be externally imaged.
The high-throughput models will be developed with the following Specific Aims:
1) Determination of organs involved with metastatic cancer that can be externally
imaged by tumor GFP expression in real-time. External imaging will be
compared with direct imaging of the fluorescent tumors; 2) Determination and
improvement of maximum depth and minimal tumor size for external imaging.
Improvements in resolution will focus on increases in the signal/background
ratio, as outlined below: 1) Ultra-bright GFP-expressing cancer cell clones
will be selected in vitro to enhance size and depth image resolution after
transplantation in vivo; 2) Selective filters, tunable laser and two-photon
imaging to maximize depth and size resolution will be used; 3) Real-time
tumor and metastatic growth and angiogenesis and inhibition by representative
drugs will be imaged and quantified to demonstrate feasibility of use of the
models for a rapid anti-tumor, anti-metastatic and anti-angiogenesis drug
screen. Dose response curves obtained by optical imaging and by standard
tumor measurements will be compared in colon, pancreas, prostate, melanoma and
lung tumor models.
PROPOSED COMMERCIAL APPLICATION:
Externally-imageable, genetically-fluorescent metastatic mouse models of all major cancer
types will be developed for rapid screening for novel effective anti-tumor, anti-metastatic
and anti-angiogenic agents. The current market size for in vivo testing of new cancer drugs
is rapidly expanding as new technologies of genomics, proteomics, and combinatorial
chemical synthesis and high-throughput in vitro screening provide provide numerous new
leads that must be tested and validated in vivo.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
--
发表时间:
2003
期刊:
Cancer research
影响因子:
11.2
作者:
[F. Sun;A. Tohgo;M. Bouvet;S. Yagi;Rounak Nassirpour;A. Moossa;R. Hoffman]
通讯作者:
F. Sun;A. Tohgo;M. Bouvet;S. Yagi;Rounak Nassirpour;A. Moossa;R. Hoffman
Determination of clonality of metastasis by cell-specific color-coded fluorescent-protein imaging.
通过细胞特异性颜色编码荧光蛋白成像确定转移克隆性。
DOI:
--
发表时间:
2003
期刊:
Cancer research.
影响因子:
--
作者:
[Yamamoto,Norio, Yang,Meng, Jiang,Ping, Xu,Mingxu, Tsuchiya,Hiroyuki, Tomita,Katsuro, Moossa,AR, Hoffman,RobertM]
通讯作者:
Hoffman,RobertM
DOI:
--
发表时间:
2002-03
期刊:
Cancer research
影响因子:
11.2
作者:
[M. Bouvet;Jinwei Wang;S. Nardin;Rounak Nassirpour;Meng Yang;E. Baranov;P. Jiang;A. Moossa;R. Hoffman]
通讯作者:
M. Bouvet;Jinwei Wang;S. Nardin;Rounak Nassirpour;Meng Yang;E. Baranov;P. Jiang;A. Moossa;R. Hoffman
DOI:
--
发表时间:
2003-07
期刊:
Cancer research
影响因子:
11.2
作者:
[A. Glinskii;Brian A. Smith;P. Jiang;Xiaoming Li;Meng Yang;R. Hoffman;G. Glinsky]
通讯作者:
A. Glinskii;Brian A. Smith;P. Jiang;Xiaoming Li;Meng Yang;R. Hoffman;G. Glinsky
Pancreatic-Cancer Imageable Patient-Derived Orthotopic Xenografts (iPDOX)
-
批准号:8780448
-
项目类别:
-
资助金额:$22.47万
-
财政年份:2014
-
负责人:MENG YANG
-
依托单位:
Therapeutic hair follicle-derived neurospheres
-
批准号:6934274
-
项目类别:
-
资助金额:$14.98万
-
财政年份:2005
-
负责人:MENG YANG
-
依托单位:
Orthotopic models of tumor angiogenesis and blood flow
-
批准号:7160990
-
项目类别:
-
资助金额:$37.48万
-
财政年份:2003
-
负责人:MENG YANG
-
依托单位:
Therapeutic hair follicle-derived neurospheres
-
批准号:7275359
-
项目类别:
-
资助金额:$37.45万
-
财政年份:2003
-
负责人:MENG YANG
-
依托单位:
Orthotopic models of tumor angiogenesis and blood flow
-
批准号:7292746
-
项目类别:
-
资助金额:$37.48万
-
财政年份:2003
-
负责人:MENG YANG
-
依托单位:
Dual-color tumor-host imaging models
-
批准号:7109037
-
项目类别:
-
资助金额:$37.58万
-
财政年份:2003
-
负责人:MENG YANG
-
依托单位:
Therapeutic hair follicle-derived neurospheres
-
批准号:7159296
-
项目类别:
-
资助金额:$37.45万
-
财政年份:2003
-
负责人:MENG YANG
-
依托单位:
Dual-color tumor-host imaging models
-
批准号:7234290
-
项目类别:
-
资助金额:$37.58万
-
财政年份:2003
-
负责人:MENG YANG
-
依托单位:
Dual-color tumor-host imaging models
-
批准号:6694637
-
项目类别:
-
资助金额:$14.98万
-
财政年份:2003
-
负责人:MENG YANG
-
依托单位:
Orthotopic models of tumor angiogenesis and blood flow
-
批准号:6582762
-
项目类别:
-
资助金额:$14.98万
-
财政年份:2003
-
负责人:MENG YANG
-
依托单位:
GFP IMAGING FOR IN VIVO HIGH-THROUGHPUT DRUG SCREENING
-
批准号:6287889
-
项目类别:
-
资助金额:$25.0万
-
财政年份:2001
-
负责人:MENG YANG
-
依托单位: